Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 948 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Granix Clear all

Conditions: Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
Interventions: Clinical Observation, Docetaxel, Doxorubicin Hydrochloride, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim; Other · Drug · Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 608
States / cities: Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 374 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions: Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 3
States / cities: Detroit, Michigan • Buffalo, New York • Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: Bortezomib, G-CSF; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neutropenia, Infection
Interventions: Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine; Drug · Biological · Device
Lead sponsor: Carelon Research; Other
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
Interventions: Allogeneic Bone Marrow Transplantation, Bendamustine, Filgrastim-sndz, Fludarabine, Inotuzumab Ozogamicin, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus; Procedure · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, leucovorin calcium, methotrexate, perfosfamide, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Up to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2003
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions: filgrastim, docetaxel; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 26 more

Conditions: Head and Neck Cancer
Interventions: Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel; Radiation · Drug · Biological
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Melphalan, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation; Drug · Biological · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions: Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Leukemia
Interventions: filgrastim, rituximab, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carmustine, cisplatin, cyclophosphamide, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Bone marrow transplantation, Cytoxan, testosterone cypionate; Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
Interventions: Cyclophosphamide, filgrastim; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 74 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions: Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells; Genetic · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, melphalan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Brain and Central Nervous System Tumors
Interventions: filgrastim, carboplatin, temozolomide; Biological · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, carboplatin, paclitaxel, topotecan hydrochloride; Biological · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma
Interventions: Ofatumumab, Ifosfamide, Etoposide, Mesna, G-CSF, Stem Cell Collection; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Tumors, Central Nervous System Tumors
Interventions: filgrastim, topotecan hydrochloride, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Multiple Myeloma
Interventions: filgrastim, melphalan, autologous peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Docetaxel in Treating Children With Recurrent Solid Tumors

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Autologous Transplant To End NMO Spectrum Disorder

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis